ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration [Yahoo! Finance]
ProQR Therapeutics N.V. - Ordinary Shares (PRQR)
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
proqr.com
Company Research
Source: Yahoo! Finance
changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced an expansion of its collaboration with the Rett Syndrome Research Trust (RSRT). Building on the initial $1 million research grant announced in January 2024 , the expanded partnership includes an additional $8.1 million in funding from the RSRT, for a total of $9.1 million. The funding will support the advancement of AX-2402 into clinical trials. Rett Syndrome, a rare and devastating neurodevelopmental disorder, affects approximately 350,000 people worldwide, predominantly girls. With no current cures and limited treatment options, Rett Syndrome presents a significant unmet medical need. AX-2402 is being developed for individuals with Rett syndrome who have the R270X mutation in MECP2 gene, and is based on ProQR's proprietary Axiomer RNA editing platform. Axiomer can target many mutations beyond R270X that collectively impact a large segment of the Re
Show less
Read more
Impact Snapshot
Event Time:
PRQR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRQR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRQR alerts
High impacting ProQR Therapeutics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRQR
News
- Is There An Opportunity With ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 37% Undervaluation? [Yahoo! Finance]Yahoo! Finance
- ProQR Therapeutics (NASDAQ: PRQR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.MarketBeat
- ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.MarketBeat
- ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing CollaborationGlobeNewswire
PRQR
Earnings
- 11/7/24 - Beat
PRQR
Sec Filings
- 12/12/24 - Form 6-K/A
- 12/11/24 - Form 6-K
- 12/11/24 - Form 6-K
- PRQR's page on the SEC website